Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study

Table 3 Univariate survival analysis in HIV negative cHL patients

Variable	cHL			MC subtype		NS subtype
Variable	N	OS	PFS	N	OS	N	OS
Demographic data
Age ≥50 yrs	97	<0.001	0.753	40	<0.001	57	0.156
Male sex	97	0.197	0.132	40	0.496	57	0.816
Clinicopathologic data
IPS >2	94	0.025	0.046	38	0.029	56	0.964
Advanced stage	95	0.006	0.092	38	0.050	57	0.336
MC or NS subtype	97	0.012	0.144
B symptom	91	0.377	0.735	37	0.812	54	0.365
Bulky disease	91	0.046	0.576	36	0.017	55	0.422
EBV infection	78	0.045	0.971	31	0.395	47	0.217
PB monocyte (≥7.1%)	90	0.652	0.402	35	0.813	55	0.076
Immunohistochemical data
IDO (≥26%)	97	<0.001	0.828	40	0.017	57	0.017
CD163 (≥33%)	77	0.002	0.958	31	0.015	46	0.137
CD68 (≥5%)	73	0.058	0.314	29	0.078	44	0.536
CD4 (≥301 cells/mm²)	79	0.916	0.684	34	0.407	45	0.761
CD8 (≥2302 cells/mm²)	76	0.813	0.527	33	0.361	43	0.758
FOXP3/CD4 (≥0.5)	79	0.313	0.835	34	0.167	45	0.843

HIV, human immunodeficiency virus; cHL, classical Hodgkin lymphoma; N, number; OS, overall survival; PFS, progression free survival; IPS, international prognostic score; MC, mixed cellularity; NS, nodular sclerosis; PB, peripheral blood; IDO, indoleamine 2,3-dioxygenase.

ISSN: 1471-2407